The following stocks are the leading risers and fallers on AIM on Thursday.
----------
AIM - WINNERS
----------
Kromek Group PLC, up 23% at 6.50 pence, 12-month range 4.30p-9.50p. The detection technology supplier reports weaker half-year revenue and a wider pretax loss, and announces a $37.5 million deal with Siemens Healthineers AG. The deal with the healthcare services provider will see Kromek provide ‘know-how and use rights of IP on a non-exclusive basis’. It will supply CZT-based detector tiles and furnaces and related services, as part of an enablement agreement and patent licensing deals. ‘Under the enablement agreement, the group will be paid a total of $37.5 million in cash in four instalments over a four-year period, with the first instalment of $25.0 million to be received in the current financial year, a material amount of which will be recognised as revenue. In addition, the directors believe the supply agreement will make a material contribution to Advanced Imaging revenue from the second year of the agreement onwards,’ Kromek adds.
----------
Inspecs Group PLC, up 14% at 44.89 pence, 12-month range 38.00p-78.00p. The designer, manufacturer and distributor of eyewear says it expects to see 2024 earnings below expectations, but it hails progress in the second half of the year. Revenue for 2024 is expected to have amounted to £200.5 million, a decline from £203.3 million in 2023. Underlying earnings before interest, tax, depreciation and amortisation of £17.5 million are expected, a decline from £18.0 million. ‘Whilst total revenue and underlying Ebitda for the group in 2024 was behind our original expectations, revenue growth was achieved in the second half of the year,’ Chief Executive Officer Richard Peck says. In the second half alone, revenue improves 5.9% on-year. Inspecs adds: ‘The group has made a solid start to 2025 and is confident of its ability to continue to reduce debt and increase margins and underlying Ebitda.’
----------
AIM - LOSERS
----------
Futura Medical PLC, down 39% at 18.98p, 12-month range 12.99p-47.80p. The sexual health products firm expects 2024 revenue and post-tax profit ahead of market expectations, but it cautions on its 2025 outturn. US sales in 2025 are to be lower than previously thought, ‘based on the pace of initial consumer uptake and general awareness’. Revenue and profit for 2025 will be ‘materially below current market expectations’. For 2024, it puts revenue and post-tax profit market expectations at £13.4 million and £500,000. For 2025, it says market expectations are for post-tax profit of £6.3 million on revenue of £18.5 million.
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
